Skip to Main Content

Paper Details

Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
Hepatol Int
5
2022
Author NameAffiliation
Laurence Brugi??resUniversite Paris-Saclay
  • 1 - 1

Datasets

Release 1.2